Vaccine advisory committee OKs Johnson & Johnson COVID-19 vaccine for adults 30+ – May 3, 2021
During a virtual news conference, members of the National Advisory Committee on Immunization (NACI) join Dr. Howard Njoo, Canada’s deputy chief public health officer, for an update on guidance regarding the Janssen COVID-19 vaccine from Johnson & Johnson. Taking part in the briefing are Drs. Caroline Quach-Thanh, chair of NACI, Shelley Deeks, vice-chair of NACI, and Matthew Tunis, executive secretary of NACI. NACI recommends that the Janssen vaccine may be offered to people ages 30 and over if the individual prefers an earlier vaccine rather than waiting for an mRNA vaccine, and if the benefits outweigh the risks. On April 30, Health Canada announced it was holding off on distributing 300,000 doses of this vaccine due to a possible quality control issue.